ES2673209T3 - Procedimientos de tratamiento del cáncer colorrectal - Google Patents
Procedimientos de tratamiento del cáncer colorrectal Download PDFInfo
- Publication number
- ES2673209T3 ES2673209T3 ES14713401.9T ES14713401T ES2673209T3 ES 2673209 T3 ES2673209 T3 ES 2673209T3 ES 14713401 T ES14713401 T ES 14713401T ES 2673209 T3 ES2673209 T3 ES 2673209T3
- Authority
- ES
- Spain
- Prior art keywords
- smad7
- cells
- antisense oligonucleotide
- colorectal cancer
- ged
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
- C12N2310/3125—Methylphosphonates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361790488P | 2013-03-15 | 2013-03-15 | |
| US201361790488P | 2013-03-15 | ||
| US201361847287P | 2013-07-17 | 2013-07-17 | |
| US201361847287P | 2013-07-17 | ||
| PCT/EP2014/055195 WO2014140333A1 (en) | 2013-03-15 | 2014-03-14 | Methods of treating colorectal cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2673209T3 true ES2673209T3 (es) | 2018-06-20 |
| ES2673209T8 ES2673209T8 (es) | 2020-02-12 |
Family
ID=50390057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14713401.9T Active ES2673209T3 (es) | 2013-03-15 | 2014-03-14 | Procedimientos de tratamiento del cáncer colorrectal |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP2970419B8 (enExample) |
| JP (2) | JP6502863B2 (enExample) |
| KR (1) | KR102232623B1 (enExample) |
| CN (1) | CN105008394B (enExample) |
| AU (1) | AU2014229985B2 (enExample) |
| CA (1) | CA2903597C (enExample) |
| ES (1) | ES2673209T3 (enExample) |
| MX (1) | MX363746B (enExample) |
| NZ (1) | NZ711564A (enExample) |
| RU (1) | RU2674147C2 (enExample) |
| WO (1) | WO2014140333A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| ES2627745T3 (es) | 2008-11-13 | 2017-07-31 | Nogra Pharma Limited | Composiciones antisentido, y procedimientos de fabricación y uso de las mismas |
| US9791442B2 (en) | 2011-09-15 | 2017-10-17 | Nogra Pharma Limited | Methods of monitoring responsiveness to anti-SMAD7 therapy |
| CN104487574B (zh) | 2012-04-18 | 2017-07-07 | 诺格尔制药有限公司 | 治疗糖尿病和/或促进胰岛移植后存活的方法 |
| US10006029B2 (en) | 2013-03-15 | 2018-06-26 | Nogra Pharma Limited | Methods of treating colorectal cancer |
| RU2016147569A (ru) | 2014-05-09 | 2018-06-13 | Ногра Фарма Лимитед | Способы лечения воспалительного заболевания кишечника |
| US10337004B2 (en) | 2014-10-17 | 2019-07-02 | Nogra Pharma Limited | Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide |
| US20180289692A1 (en) * | 2015-09-30 | 2018-10-11 | Celgene Corporation | Tlr modulators and methods of use |
| US11162097B2 (en) | 2016-02-23 | 2021-11-02 | Nogra Pharma Limited | Methods of treating intestinal fibrosis using SMAD7 inhibition |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6159697A (en) * | 2000-01-19 | 2000-12-12 | Isis Pharmaceuticals, Inc. | Antisense modulation of Smad7 expression |
| ITRM20030149A1 (it) * | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| ITRM20030393A1 (it) * | 2003-08-11 | 2005-02-12 | Giuliani Spa | Uso di oligonucleotidi (odn) antisenso per smad7 per il trattamento delle patologie mediate dal fattore di trascrizione nucleare nf-kb. |
| US7402574B2 (en) * | 2004-03-12 | 2008-07-22 | Avi Biopharma, Inc. | Antisense composition and method for treating cancer |
| US20080114287A1 (en) * | 2006-11-14 | 2008-05-15 | Kar Neng Lai | Ultrasound Microbubble Mediated Genes Delivery System |
| ES2627745T3 (es) * | 2008-11-13 | 2017-07-31 | Nogra Pharma Limited | Composiciones antisentido, y procedimientos de fabricación y uso de las mismas |
| UA107562C2 (uk) * | 2008-12-05 | 2015-01-26 | Спосіб лікування псоріазу | |
| US9791442B2 (en) * | 2011-09-15 | 2017-10-17 | Nogra Pharma Limited | Methods of monitoring responsiveness to anti-SMAD7 therapy |
-
2014
- 2014-03-14 EP EP14713401.9A patent/EP2970419B8/en active Active
- 2014-03-14 CA CA2903597A patent/CA2903597C/en active Active
- 2014-03-14 KR KR1020157029231A patent/KR102232623B1/ko active Active
- 2014-03-14 NZ NZ711564A patent/NZ711564A/en unknown
- 2014-03-14 MX MX2015013255A patent/MX363746B/es active IP Right Grant
- 2014-03-14 WO PCT/EP2014/055195 patent/WO2014140333A1/en not_active Ceased
- 2014-03-14 JP JP2015562243A patent/JP6502863B2/ja active Active
- 2014-03-14 ES ES14713401.9T patent/ES2673209T3/es active Active
- 2014-03-14 AU AU2014229985A patent/AU2014229985B2/en active Active
- 2014-03-14 CN CN201480016188.7A patent/CN105008394B/zh active Active
- 2014-03-14 RU RU2015140572A patent/RU2674147C2/ru active
-
2018
- 2018-10-23 JP JP2018199148A patent/JP2019026649A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| MX2015013255A (es) | 2015-12-15 |
| AU2014229985A1 (en) | 2015-09-10 |
| JP6502863B2 (ja) | 2019-04-17 |
| ES2673209T8 (es) | 2020-02-12 |
| RU2674147C2 (ru) | 2018-12-05 |
| CA2903597C (en) | 2023-04-04 |
| RU2015140572A3 (enExample) | 2018-03-21 |
| RU2015140572A (ru) | 2017-04-24 |
| KR20150131260A (ko) | 2015-11-24 |
| AU2014229985B2 (en) | 2018-12-13 |
| MX363746B (es) | 2019-04-01 |
| WO2014140333A1 (en) | 2014-09-18 |
| JP2016517401A (ja) | 2016-06-16 |
| EP2970419B1 (en) | 2018-05-09 |
| NZ711564A (en) | 2020-04-24 |
| CN105008394B (zh) | 2021-10-22 |
| KR102232623B1 (ko) | 2021-03-26 |
| JP2019026649A (ja) | 2019-02-21 |
| EP2970419B8 (en) | 2019-12-11 |
| HK1219489A1 (en) | 2017-04-07 |
| CN105008394A (zh) | 2015-10-28 |
| CA2903597A1 (en) | 2014-09-18 |
| EP2970419A1 (en) | 2016-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6502863B2 (ja) | 結腸直腸癌を処置する方法 | |
| ES2952032T3 (es) | Administración de mononucleótido de nicotinamida en el tratamiento de ojo seco | |
| KR102118429B1 (ko) | 마이크로rna 화합물 및 mir-21 활성 조절 방법 | |
| US10006029B2 (en) | Methods of treating colorectal cancer | |
| Johnson et al. | Protease-activated receptor-2 (PAR-2)-mediated NF-κB activation suppresses inflammation-associated tumor suppressor microRNAs in oral squamous cell carcinoma | |
| EA023864B1 (ru) | Применение мацитентана в комбинации с цитотоксическим химиотерапевтическим средством и/или лучевой терапией для лечения метастазов в головном мозге | |
| JP2011506343A (ja) | トポイソメラーゼ阻害剤とｐａｒｐ阻害剤との組み合わせによるがんの治療 | |
| WO2017189553A1 (en) | Removal of senescence-associated macrophages | |
| Fréour et al. | TACE inhibition amplifies TNF-α-mediated colonic epithelial barrier disruption | |
| WO2014082085A1 (en) | Use of itk inhibitors for the treatment of cancer | |
| JP2018523696A (ja) | 肝疾患および状態を治療する方法および組成物 | |
| US9845471B2 (en) | Compositions and methods for treating pancreatic cancer | |
| Liao et al. | Multi-omics profiling of retinal pigment epithelium reveals enhancer-driven activation of RANK-NFATc1 signaling in traumatic proliferative vitreoretinopathy | |
| ES2882954T3 (es) | Usos médicos que comprenden métodos para la medición de la inhibición de la quinasa c-Jun N-terminal en la piel | |
| JP7797384B2 (ja) | 循環からミトコンドリアｄｎａ又はゲノムｄｎａを枯渇させることにより疾患及び症状を治療する組成物及び方法 | |
| ES2861516T3 (es) | Oligonucleótidos antisentido para IL-34 y métodos de uso de los mismos | |
| WO2016187486A1 (en) | Biomarkers and uses thereof for selecting pancreas cancer intervention | |
| HK1219489B (en) | Methods of treating colorectal cancer | |
| CN113748207A (zh) | 脆性x智力低下蛋白干扰寡核苷酸及其使用方法 | |
| Guan et al. | Targeting the FAPα/Integrin αvβ1 complex attenuates hepatic stellate cell activation and liver fibrosis | |
| TWI602572B (zh) | 抗菌胜肽tp4治療癌症之用途 | |
| Kim | The effect of tumor microenvironmental stress on malignant mesothelioma | |
| IL324326A (en) | Compounds for nos-related cancers and methods of use | |
| Dropmann | TGF-β2 abundance in mice and men: A successful anti-TGF-β2 strategy in biliary-derived liver disease | |
| EA045399B1 (ru) | Олигонуклеотиды, препятствующие экспрессии белка, ассоциированного с синдромом ломкой х-хромосомы, и способы их применения |